DANBURY, Conn., April 12 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals Co. will conduct a conference call on Thursday, April 26, at 11:00 a.m. EDT to review its financial results for the first quarter of 2007, which will be released earlier that day. Operational developments and financial outlook will also be discussed on the call.
The conference call will include remarks by Jennifer Good, President and Chief Executive Officer, and Benjamin Palleiko, Senior Vice President, Corporate Development and Chief Financial Officer.
Domestic Telephone Number: 877-809-3716 International Telephone Number: 706-634-9511 The conference ID is "5343822."
Please dial in 10 minutes prior to the scheduled start time. The conference call will also be accessible live and as a replay on the Investor Relations section of the Penwest Web site at http://www.penwest.com.
Penwest Pharmaceuticals
Penwest is a specialty pharmaceutical company dedicated to bringing to the marketplace innovative products that help improve the lives of patients. The Company's goal is to identify, develop and commercialize prescription products that address unmet medical needs, primarily for diseases of the nervous system. At the core of this strategy, Penwest applies drug delivery technologies, including its own proprietary technologies, to new and existing compounds to enhance their therapeutic profiles. The launch by Endo Pharmaceuticals in mid-2006 of Opana(R) ER (oxymorphone hydrochloride extended-release tablets) formulated with the Company's TIMERx(R) extended release delivery technology demonstrates the execution of this strategy and the value of the Company's TIMERx technology. The Company is currently applying its expertise to a pipeline of potential products that are in various stages of development. The Company intends to commercialize these products independently or through third party alliances.
The matters discussed herein contain forward-looking statements that involve risks and uncertainties, which may cause Penwest's actual results in future periods to be materially different from any future performance suggested herein. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words, "believes," "anticipates," "plans," "expects," "intends," "potential," and similar expressions are intended to identify forward-looking statements. Important factors that could cause results to differ materially include: uncertainty of success of collaborations; including the collaboration with PII including the risk that such collaboration does not result in new licensing opportunities; risks relating to the commercial success of our products; regulatory risks relating to drugs in development, including the timing and outcome of regulatory action; the timing of clinical trials and whether the results of clinical trials will warrant further clinical trials or warrant submission of an application for regulatory approval of, or the regulatory approval of, the product that is the subject of the trial; actual and potential competition; the need for capital; and other risks as set forth under the caption Risk Factors in Penwest's Annual Report on Form 10-k filed with the Securities and Exchange Commission on March 16, 2007, which risk factors are incorporated herein by reference.
The forward-looking statements contained in this press release speak only as of the date of the statement made. Penwest disclaims any intention or obligation to update any forward-looking statements.
Contacts: Investors: Media: Diane D'Alessandro Laura Walters (203) 796-3706 Kekst and Company (877) 736-9378 (212) 521-4800
Penwest Pharmaceuticals Co.CONTACT: Investors, Diane D'Alessandro, +1-203-796-3706, +1-877-736-9378;or Media, Laura Walters of Kekst and Company, +1-212-521-4800, both forPenwest Pharmaceuticals Co.
Web site: http://www.penwest.com/
